Details for New Drug Application (NDA): 207923
✉ Email this page to a colleague
The generic ingredient in SEEBRI is glycopyrrolate. There are seventeen drug master file entries for this compound. Fifty-six suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.
Summary for 207923
Tradename: | SEEBRI |
Applicant: | Novartis |
Ingredient: | glycopyrrolate |
Patents: | 2 |
Medical Subject Heading (MeSH) Categories for 207923
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | POWDER;INHALATION | Strength | 15.6MCG/INH | ||||
Approval Date: | Oct 29, 2015 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Oct 20, 2028 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Sign Up | Patent Expiration: | Oct 11, 2028 | Product Flag? | Y | Substance Flag? | Delist Request? |
Expired US Patents for NDA 207923
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | SEEBRI | glycopyrrolate | POWDER;INHALATION | 207923-001 | Oct 29, 2015 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription